ascopubs.org: Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
A dose of medicine or a drug is a measured amount of it which is intended to be taken at one time.
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Many drugs in development continue to follow the historical drug development ...
RAPS: With Dose Optimization Failures at Staggering Levels, FDA Readies New Regulatory Efforts
US regulators are planning to hold a meeting on emerging modeling methods that could be used to fine-tune dose selection studies and decision-making. Dose optimization is one of the most crucial parts ...
With Dose Optimization Failures at Staggering Levels, FDA Readies New Regulatory Efforts
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
Nasdaq: Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases, Supported by $17.6M Grant from CPRIT
Plus Therapeutics, Inc. has announced the initiation of the ReSPECT-LM dose optimization trial for its product REYOBIQ™ (rhenium Re186 obisbemeda) aimed at treating leptomeningeal metastases (LM).
Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases, Supported by $17.6M Grant from CPRIT